Clinical efficacy of CT-guided 125I brachytherapy in patients with local residual or recurrent hepatocellular carcinoma after thermal ablation
Key points 125I brachytherapy is a treatment for locally recurrent HCC after ablation. 125I brachytherapy combined with ablation may improve tumor control. Vascular invasion, multiple lesions, and AFP are prognostic risk factors. 125I brachytherapy is a safe method with a curative effect.
Main Authors: | Wenliang Zhu, Zhihui Zhong, Huzheng Yan, Huanqing Guo, Meigui Xiao, Xu He, Fei Gao, Fujun Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-12-01
|
Series: | Insights into Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13244-022-01327-z |
Similar Items
-
CT-guided 125I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study
by: Chen Zixiong, et al.
Published: (2023-03-01) -
CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study
by: Xu X, et al.
Published: (2021-04-01) -
CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer
by: Juan Wang, et al.
Published: (2023-08-01) -
Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
by: Congxiao Wang, et al.
Published: (2020-06-01) -
A Robust Oxygen Microbubble Radiosensitizer for Iodine‐125 Brachytherapy
by: Sheng Peng, et al.
Published: (2021-04-01)